Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

NEWPORT BEACH, Calif.–(BUSINESS WIRE)—- $EOLS–Evolus enrolls its first patient in a clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs).